The Centers for Disease Control and Prevention (CDC) is announcing the availability of about $70 million in supplemental funding to states, cities, and territories to support continued efforts to protect Americans from Zika virus.
The funding, distributed through CDC’s Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, will further support activities to protect the health of Americans, especially pregnant women, including epidemiologic surveillance and investigation, improving mosquito control and monitoring, and strengthening laboratory capacity. Funding also will support participation in the U.S. Zika Pregnancy Registry to monitor pregnant women with Zika and their infants.
States were notified of the funding opportunity announcement on Oct. 19, 2016. All ELC applicants can request funds. The distribution of funds will be determined based on factors such as Zika disease burden, current laboratory and mosquito surveillance and control capacity, the presence of the Zika virus vector (Aedes aegypti and Aedes albopictus mosquitoes), and local Zika virus transmission. CDC continues to work with states and territories to provide emergency resources for critical needs while the agency completes the necessary reviews and approvals of all applications.
The deadline for applications is 11:59 p.m. ET on Nov. 20. For more information on CDC’s ELC Cooperative Agreement, visit the ELC webpage: http://www.cdc.gov/ncezid/dpei/epidemiology-laboratory-capacity.html.
Second Strain of Bird Flu Found in US Dairy Cows: What It Means for Infection Prevention and Control
February 7th 2025A new H5N1 strain was found in Nevada dairy cows, challenging earlier transmission theories. This raises concerns about animal vulnerability, human health risks, and food safety. Experts emphasize the need for improved surveillance, biosecurity, and cross-sector collaboration to contain the virus spread.
Fungal Infections: The Silent Epidemic Threatening Global Health
February 6th 2025Fungal infections are a rising global threat, with antifungal resistance complicating treatment. Neil J. Clancy, MD, emphasizes the urgent need for research, better diagnostics, and stronger infection prevention strategies.
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.